Mucormycosis Treatment Market Forecasting to 2030 Top Companies Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG

The Global Mucormycosis Treatment Market is estimated to reach a value of USD 914.6 million in 2021, and is projected to grow at a CAGR of 8.2% during the forecast period. Mucormycosis is a rare but serious fungal infection caused by a group of molds termed as mucormycetes. Furthermore, inhaling fungal spores from the air can affect the sinuses and lungs. The fungus also attacks the skin through wounds such as burn, cut, or other type of skin trauma.
The recent rise in COVID-19 cases has surged the treatment of mucormycosis in COVID-19 survivors. Mucormycosis infection is more likely affecting the recovered patients probably due to prolonged administration of immunosuppressant and steroid medications. COVID-19 patients with diabetic and pre-existing comorbidities people exposed to steroids and humidified oxygen for an extended period are at maximum risk of mucormycosis. This is expected to contribute to the demand for mucormycosis treatment during the forecast period.

Get Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-69825?utm_source=OpenPR/PratikshaP

-Recent Developments in the Global Mucormycosis Treatment Market:
• March 2021- Bharat Serums & Vaccines (BSV)
became the first Indian firm to receive
authorization from the Drugs Controller
General of India (DCGI) for Liposomal
Amphotericin B, an antifungal medicine used
for the treatment of mucormycosis.
• May 2021- TLC Pharma, a clinical-stage
specialty pharmaceutical company, received
authorization for the New Drug Application
(NDA) for Amphotericin B liposome injection
(AmphoTLC), from the Central Drugs Standard
Control Organization (CDSCO) of India.
• May 2021- Cadila Healthcare Limited and TLC
Pharma Labs, came into a contract to
manufacture anti-fungal drug ‘Liposomal
Amphotericin B’ for the treatment of black
fungus or mucormycosis in India.

-Market Segmentation:
-By Type
• Rhizopus
• Rhizomucor
• Cunninghamella
• Apophysomyces
• Saksenaea
• Lichtheimia

-By Diagnosis
• CT
• MRI
• Tissue Biopsy

-By Treatment
• Surgery
• Antifungal

-By End User
• Hospitals
• Clinics
• Others

By Region:
North America Mucormycosis Treatment Market
• North America, by Country
o U.S
o Canada
o Mexico
• North America, by Type
• North America, by Diagnosis
• North America, by Treatment
• North America, by End User

Europe Mucormycosis Treatment Market
• Europe, by Country
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
• Europe by Type
• Europe, by Diagnosis
• Europe, by Treatment
• Europe, by End User

Asia Pacific Mucormycosis Treatment Market
• Asia Pacific, by Country
o China
o India
o Japan
o South Korea
o Australia
o Rest of Asia Pacific
• Asia Pacific, by Type
• Asia Pacific, by Diagnosis
• Asia Pacific, by Treatment
• Asia Pacific, by End User

Middle East and Africa Mucormycosis Treatment Market
• Middle East and Africa, by Country
o UAE
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East and Africa
• Middle East and Africa, by Type
• Middle East and Africa, by Diagnosis
• Middle East and Africa, by Treatment
• Middle East and Africa, by End User

South America Mucormycosis Treatment Market
• South America, by Country
o Brazil
o Argentina
o Rest of South America
• South America by Type
• South America, by Diagnosis
• South America, by Treatment
• South America, by End User

Major Companies: In this report, the major companies studied are: Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb, Bayer AG, Lonza Group, Sanofi, Johnson & Johnson, Pfizer Inc., and Gilead Sciences.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-69825?utm_source=OpenPR/PratikshaP

Objectives of this Report:
• To estimate the market size for the
mucormycosis treatment market on a regional
and global basis
• To identify major segments in the
mucormycosis treatment market and evaluate
their market shares and demand
• To provide a competitive scenario for the
market with major developments observed by
the key companies in the historic years
• To evaluate the leading company-wise pricing
analysis for the mentioned applications

Key Questioned Answered in the Study:
• What are major growth drivers and market
trends that are impacting the global
mucormycosis treatment market?
• What is the market size both in terms of value
and volume for the global mucormycosis
treatment market?
• Who are the leading market players and who
are the new market players that operate in
the global market with an estimated market
share?
• What are the future investment pockets and
opportunities in the global mucormycosis
treatment market?
• Major list of customers and potential
futuristic customer list along with an
estimated buying volume
• Impact of COVID-19 on the global
mucormycosis treatment market

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-69825?utm_source=OpenPR/PratikshaP

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144

Email: sales@quincemarketinsights.com

Web: https://www.quincemarketinsights.com

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.